SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: former_pgs who wrote (352)12/20/2004 6:13:13 PM
From: Icebrg  Respond to of 946
 
The marketing decision will, according to Bianco, be depending on what type of label they can get. The broader the label the more likely a marketing partnership will become.

Bianco has followed the Golden Rule for Biotech CxOs. If there is money available, then just TAKE IT. Don't ask any stupid questions. Etc.

But as I wrote, the small amount looks suspicious. Surely, he would have been able to raise more, if he really wanted to.

All the pieces don't fit in this puzzle yet.

Erik



To: former_pgs who wrote (352)12/20/2004 6:14:28 PM
From: Rocky9  Read Replies (1) | Respond to of 946
 
Why are the March call options still so high? With the news on the results delayed, shouldn't the volatility be reduced too? Or is the market saying that the results may still happen before the March expiration date?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News